BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
2737629
Number of visits today
955
Number of downloads
2008993
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Ganji C, Farran B. Current clinical trials for epigenetic targets and therapeutic inhibitors for pancreatic cancer therapy. Drug Discov Today 2021:S1359-6446(21)00563-8. [PMID: 34952224 DOI: 10.1016/j.drudis.2021.12.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Hu W, Li M, Wang Y, Zhong C, Si X, Shi X, Wang Z. Comprehensive bioinformatics analysis reveals the significance of forkhead box family members in pancreatic adenocarcinoma. Aging (Albany NY) 2023;15:92-107. [PMID: 36622275 DOI: 10.18632/aging.204455] [Reference Citation Analysis]
2 Chen X, Yuan Q, Liu J, Xia S, Shi X, Su Y, Wang Z, Li S, Shang D. Comprehensive characterization of extracellular matrix-related genes in PAAD identified a novel prognostic panel related to clinical outcomes and immune microenvironment: A silico analysis with in vivo and vitro validation. Front Immunol 2022;13:985911. [DOI: 10.3389/fimmu.2022.985911] [Reference Citation Analysis]
3 Koltai T, Reshkin SJ, Carvalho TMA, Di Molfetta D, Greco MR, Alfarouk KO, Cardone RA. Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. Cancers (Basel) 2022;14:2486. [PMID: 35626089 DOI: 10.3390/cancers14102486] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345